On July 15, 2026 Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, reported its partnership with Nouveau Biosciences, Inc. to conduct cancer focused clinical trials for their lead asset Kromastat. Nouveau Biosciences is a biotechnology company pioneering novel targeted nanomedicines to improve cancer therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Nouveau Biosciences has developed a proprietary drug discovery technology coupled to a polymer-based nanochemistry capability that enhances drug targeting, tolerability and efficacy. The platform enables the creation of novel anticancer agents that are now emerging as first-in-class and best-in-disease.
Kromastat (formerly known as NBS-M001) is a novel polymeric nanoparticle (PNP) of a highly potent epigenetic drug. Based on preclinical studies Kromastat is among one of the most potent drugs developed for pancreatic cancer, challenging T-cell malignancies and aggressive leukemia. The First-in-Human study will be conducted at leading academic medical centers in Australia, with a goal to rapidly move the drug into Phase 2 studies in the U.S. where the company will pursue a 505(b)2 regulatory strategy.
This collaboration underscores the commitment of both organizations to address significant unmet medical needs across cancer and accelerate the delivery of innovative therapies to patients worldwide.
Under this partnership, Anova will leverage its AnovaOS platform and comprehensive approach to accelerate clinical development of Kromastat. The partnership is poised to ensure the trial’s successful execution and bring new hope to patients globally.
"Anova is proud to collaborate with Nouveau Biosciences on this novel targeted nanomedicine," said Chris Beardmore, CEO of Anova. "We are proud to partner with Nouveau Biosciences to advance a highly differentiated nanomedicine pipeline with the potential to redefine treatment paradigms in oncology. By combining their cutting-edge science with Anova’s technology-enabled clinical delivery platform, we are uniquely positioned to accelerate development timelines, enhance execution certainty, and bring innovative therapies to patients with greater speed and precision."
"Nouveau Biosciences is deeply committed to accelerating the advancement of our pipeline through smart, execution-focused partnerships," said Owen A. O’Connor, M.D., Ph.D., Chief Executive Officer and Chairman of Nouveau Biosciences. "By working with Anova, we are integrating our innovative nanomedicine platform into a proven clinical development engine—enabling us to move more rapidly, de-risk our programs, and bring transformative therapies to patients with greater urgency."
(Press release, Nouveau Biosciences, JUL 15, 2026, View Source [SID1234669240])